Author Archives: admin


Bone paste could provide treatment for ostoeporosis …

About three million Briton currently suffer osteoporosis which is affected by a number factors such as genes, a lack of exercise and poor diet and results in about 60,000 hip, 50,000 wrist and 120,000 spinal fractures every year, according to the National Osteoporosis Society, costing about 1.7 billion in health and social care.

Dr Ifty Ahmed, a researcher at Nottingham University, said his team wanted to provide a preventative treatment, strengthening the bones of those at risk before they suffered a fracture.

Speaking at the Regener8 conference on regenerative medicine, in Leeds last week, he said: Our aim would be to use screening to spot people who are at risk, then strengthen their bones before they get fractures.

It means that rather than waiting until people have a fall and break something, we would try to stop that ever happening, along with the consequences, loss of independence, surgery and secondary illnesses.

Previous attempts have been made to find ways of strengthening thinning bones but the difficulties of protecting the fragile stem cells has meant no such treatments have yet been developed.

Dr Ahmeds team hope to overcome this problem by puncturing the tiny hollow spheres of calcium phosphate allowing the stem cells to migrate inside them where they are protected.

The experimental treatment has not yet been trialled on humans.

It would involve extracting stem cells from a patients bone marrow and mixing them with the microspheres before injecting the paste into the vulnerable bones.

Dr Ahmed said: "If it works, this kind of treatment could be done in a day.

Until now the team have been funded by the Engineering and Physical Sciences Research Council but they are now looking for a commercial partner.

Read this article:
Bone paste could provide treatment for ostoeporosis ...

Scientists Report Highly Efficient Method for Making Stem …

At NYU Langone Medical Center, scientists have found a way to boost dramatically the efficiency of the process for turning adult cells into so-called pluripotent stem cells by combining three well-known compounds, including vitamin C.

"This big boost in efficiency gives us an opportunity now to study stem cell programming mechanisms at high resolution," says Matthias Stadtfeld, PhD, assistant professor of cell biology and a member of the Skirball Institute of Biomolecular Medicine and the Helen L. and Martin S. Kimmel Center for Stem Cell Biology at NYU Langone Medical Center, who led the research."This is a very exciting advance," says Ruth Lehmann, PhD, director of the Kimmel Center for Stem Cell Biology and the Skirball Institute at NYU Langone and chair of the Department of Cell Biology. "The new technology developed by the Stadtfeld lab to reprogram differentiated cells efficiently and effectively brings the prospect of stem cell technology for safe use in regenerative medicine ever so much closer."

The standard method for reprogramming skin, blood, or other tissue-specific cell types into "induced pluripotent stem cells" (iPSCs) was reported in 2006 by the laboratory of Kyoto University's Shinya Yamanaka, who later won a Nobel Prize for the achievement. The method involves the artificial expression of four key genes dubbed OKSM (for Oct4, Klf4, Sox2 and myc) whose collective activity slowly prods cells into an immature state much like that of an early embryonic cell. In principle, one could take a sample of cells from a person, induce the cells to become iPSCs, then multiply the iPSCs in a lab dish and stimulate them to mature towards desired adult cell types such as blood, brain or heartwhich then could be used to replace injured or diseased tissue in that same individual.

But there are many formidable technical obstacles, among which is the low efficiency of currently used protocols. Converting most cell types into stable iPSCs occurs at rates of 1 percent or less, and the process can take weeks.Researchers throughout the world have been searching for ways to boost this efficiency, and in some cases have reported significant gains. These procedures, however, often alter vital cellular genes, which may cause problems for potential therapies. For the new study, reported online today in Stem Cell Reports, Dr. Stadtfeld and his laboratory team decided to take a less invasive approach and investigate chemical compounds that transiently modulate enzymes that are present in most cells.

"We especially wanted to know if these compounds could be combined to obtain stem cells at high efficiency," Dr. Stadtfeld says.Two of these compounds influence well known signaling pathways, called Wnt and TGF-, which regulate multiple growth-related processes in cells. The third is vitamin C (also known as ascorbic acid). Best known as a powerful antioxidant, the vitamin was recently discovered to assist in iPSC induction by activating enzymes that remodel chromatinthe spiral scaffold for DNAto regulate gene expression.Simon Vidal, a graduate student in the Stadtfeld lab, and Bhishma Amlani, a postdoctoral researcher, looked first at mouse skin fibroblasts, the most common cell type used for iPSC research. Adding to fibroblasts engineered to express OKSM either vitamin C, a compound to activate Wnt signaling, or a compound to inhibit TGF- signaling increased iPSC-induction efficiency weakly to about 1% after a week of cell culture.

Combining any two worked a bit better. But combining all three brought the efficiency to about 80 percent in the same period of time.In another series of experiments the team worked with blood progenitor cells, which usually replace blood cells lost after injury or infection. The OKSM method on its own can slowly convert these cells to stem cells with up to 30 percent efficiency. Using OKSM together with the three compounds brought the efficiency to nearly 100 percent in less than a week. The researchers also achieved nearly 100-percent yield in mouse liver progenitor cells.Dr. Stadtfeld expects that these dramatic increases in conversion rates of adult cells into embryonic-like stem cells will facilitate future studies of the iPSC induction process, simply by making that induction a more predictable event.

"It's just a lot easier this way to study the mechanisms that govern reprogramming, as well as detect any undesired features that might develop in iPSCs," he said.Vitamin C and the two compounds used to manipulate the Wnt and TGF- pathways are widely studied and considered to have few unknown or hazardous effects, the researchers said. By contrast, the use of OKSM has in some cases caused undesired features in iPSCs, such as developmental defects. By making iPSC induction more rapid and efficient, though, Dr. Stadtfeld's new technique might also make the resulting stem cells safer. "Conceivably it reduces the risk of abnormalities by smoothening out the reprogramming process," Dr. Stadtfeld says. "That's one of the issues we're following up."

Visit link:
Scientists Report Highly Efficient Method for Making Stem ...

Molecule boosts stem cells in cord blood: Canadian study

TORONTO Canadian researchers have found a way to boost the number of stem cells in umbilical cord blood so more patients with leukemia and other blood-related cancers could receive potentially life-saving transplants.

The key to the breakthrough technique is a molecule developed at the Universite de Montreal, coupled with a bioreactor designed at the University of Toronto, which allows scientists to significantly expand the number of stem cells from a single unit of cord blood.

Basically its going to give access to about 10 times as many cords in (cord blood) banks, said Dr. Guy Sauvageau, principal investigator of stem cell genetics at the Institute for Research in Immunology and Cancer at the Montreal university. Its as if you were to multiply by 10 today the number of cord blood units in the world.

The molecule, called UM171, was discovered serendipitously. It had been created by a chemist at the institute working on another program but didnt work for its intended purpose, so they just threw it in what we call a library of compounds, Sauvageau said Thursday from Montreal.

When his research team began testing compounds from among thousands in the library, UM171 was the only one that really worked.

Stem cells from donated umbilical cord blood are able to give rise to all the types of cells that make up blood, including the immune cells that protect the body and fight infection. The same is true of bone marrow, but finding a suitable donor is more difficult.

For some people with blood-related cancers like leukemia, myeloma and lymphoma, getting a stem cell transplant to replace their own blood system is often the treatment of last resort.

But the biggest hurdle for doctors is finding enough cord blood stem cells that are a compatible match and wont cause severe rejection symptoms in recipients, he said. Typically, there are not enough stem cells in a single cord blood unit to regenerate an adults blood system; only five per cent of cord blood bank units can be used for large adults.

And theres another reason why this is becoming more of a problem, because we have more and more ethnic groups in our society and these peoples access to a matched unrelated donor is more limited than for most Caucasians.

That was the case for Mai Duong of Montreal, who is fighting her second bout of leukemia. The 34-year-old mother had made a desperate online plea and a global search for a donor of either bone marrow or cord blood stem cells for a transplant. On Tuesday, doctors announced an unidentified woman had donated her infants umbilical cord to the Vietnamese-Canadian to help save her life.

Originally posted here:
Molecule boosts stem cells in cord blood: Canadian study

Midwest Stem Cell Therapy Center, University of Kansas …

In 2013, the Kansas Legislature and Governor Sam Brownback approved the formation of the Midwest Stem Cell Therapy Center (MSCTC). The center is housed within the University of Kansas Medical Center campus in Kansas City, Kansas. The MSCTC is designed to serve as a hub of adult stem cell therapy, research, and education in the State of Kansas and the adjoining region.

The MSCTC faculty and staff include physicians, scientists, and trainees representing the fields of adult stem cell biology, neurology, oncology, hematology, cardiac and vascular, endocrine, and other subspecialties. These individuals represent several local and regional institutions, enabling the formation of a stem cell network of knowledge and information. This synergy among various institutions also fosters productive collaborations that may result in faster translation of basic science discoveries into the clinic.

It is because of this outstanding team of dedicated members, the MSCTC has made significant strides in the relatively short time since its inception. Indeed, the MSCTC now houses a fully functional GMP operation that has been processing cells for human therapy. One clinical trial with bone marrow cells has been initiated, and several future clinical trials with adult stem cells are in the start-up phase. In addition, cutting edge molecular stem cell research is being conducted by MSCTC scientists. These ongoing studies involve induced pluripotent stem cells, regulation of cellular differentiation, cord blood cells, as well as various transcription factors and other molecular pathways in adult stem cells.

Besides clinical trials and basic research, dissemination of information regarding adult stem cell treatment options for various diseases is a major goal of MSCTC. The web portals for these informational modules are currently under construction. In addition, the MSCTC is planning to expand the training of postdoctoral fellows in basic research in adult stem cell biology, as well as clinicians in adult stem cell-related topics. Our goal is to further broaden the multidisciplinary range of expertise available within MSCTC. Also related to education, the first Midwest Conference on Cell Therapy and Regenerative Medicine was held under the auspices of MSCTC in November 2013. This meeting was extremely well received by the varied audience. We intend to hold the 2014 meeting on Sep 19-20.

Despite this rapid progress, it should be recognized that the MSCTC is a very recent and rather nascent phenomenon. We have a very long way to go. At the same time, we are very stimulated by the support and enthusiasm surrounding the MSCTC - and remain firmly committed to promoting adult stem cell therapy and research - so that patients with often incurable diseases may have hope.

Thank you for visiting. We hope to count on your support toward improving lives with adult stem cells!

Buddhadeb Dawn, M.D. Director, Midwest Stem Cell Therapy Center

Last modified: Apr 24, 2014

Read more:
Midwest Stem Cell Therapy Center, University of Kansas ...

BioTimes Subsidiary Cell Cure Neurosciences Ltd. Demonstrates the Safety and Efficacy of OpRegen in Preclinical …

We are very pleased with the safety data obtained in two animal species that demonstrate that OpRegen cells survive following transplantation for a long period of time and do not result in teratoma formation or any other type of pathology. The efficacy of the OpRegen cells was evaluated in the Royal College of Surgery rat model of retinal degeneration, which is a well-established animal model of retinal degeneration which has been extensively used to evaluate various potential cell therapies. The OpRegen cells were found to remain therapeutically functional over long periods and to maintain the animals visual performance that would normally decay over time in this disease model, said Benjamin Reubinoff, MD, PhD, Chief Scientific Officer of Cell Cure and Chairman of Obstetrics and Gynecology and Director of the Hadassah Human Embryonic Stem Cell Research Center at Hadassah Medical Center, Jerusalem, Israel. Furthermore, the protection of the animals vision from decay was dose dependent. As an additional indicator of therapeutic potential, the number of cone photoreceptors, which are responsible for fine vision in humans and are degenerating in the macula of dry-AMD patients, was found to remain constant over an extended period in the animal model.

We are very pleased with the progress that Cell Cures team has made in preparing for the companys FDA submission, said Charles S. Irving PhD, Cell Cures CEO. We look forward to initiating the clinical trial that will utilize for the first time high quality, xeno-free grade RPE cells for the treatment of geographic atrophy, the severe stage of dry-AMD.

About Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is one of the major diseases of aging and is the leading cause of visual impairment in Americans 55 years of age and older. AMD affects the macula, which is the part of the retina responsible for sharp, central vision that is important for facial recognition, reading and driving. There are two forms of AMD. The dry form (dry-AMD) advances slowly and painlessly until it reaches the severe form called geographic atrophy (GA), which may result in legal blindness. About 10% of patients with dry-AMD develop wet-AMD, which is an acute disease and can lead to blindness in a matter of weeks. Wet-AMD can be treated with currently-marketed angiogenesis inhibitors such as Lucentis or Eylea, however, such products typically require frequent injections, and patients often continue to suffer from the continued progression of the underlying dry-AMD disease process. There is no FDA-approved treatment for dry-AMD for which some seven million people in the US have the intermediate form of the disease and have a high risk for developing GA. The market opportunity for a treatment for GA has been estimated at over $5 billion globally. Current estimated sales of angiogenesis inhibitors for the treatment of the wet form of AMD are estimated to be about $7 billion worldwide. The root cause of the larger problem of dry-AMD is believed to be the degeneration of a particular type of cell in the retina called "retinal pigment epithelial" (RPE) cells. One of the most exciting therapeutic approaches to dry-AMD is the transplantation of healthy, young RPE cells to replace the patients old degenerating RPE cells. One of the most promising sources of healthy RPE cells is from pluripotent stem cells.

About OpRegen

Cell Cure's OpRegen consists of RPE cells that are produced using a proprietary process that drives the differentiation of human embryonic stem cells into high purity RPE cells. OpRegen is also xeno-free", meaning that no animal products were used either in the derivation and expansion of the human embryonic stem cells or in the directed differentiation process. The avoidance of the use of animal products eliminates some safety concerns. OpRegen is formulated as a suspension of RPE cells. Preclinical studies in mice have shown that OpRegen transplanted subretinally as a suspension of cells can rapidly organize into their natural monolayer structure and survive throughout the lifetime of the animal. OpRegen will be an off-the-shelf allogeneic product provided to retinal surgeons in a final formulation ready for transplantation. Unlike treatments that require multiple injections into the eye, such as currently-marketed products like Lucentis and Eylea for wet-AMD, it is expected that OpRegen will be administered in a single procedure.

About Cell Cure Neurosciences Ltd.

Cell Cure Neurosciences Ltd. was established in 2005 as a subsidiary of ES Cell International Pte. Ltd. (ESI), now a subsidiary of BioTime, Inc. (NYSE MKT: BTX). Cell Cures second largest shareholder is HBL Hadasit Bio-Holdings, (TASE: HDST, OTC: HADSY). Cell Cure is located in Jerusalem, Israel on the campus of Hadassah Medical Center. Cell Cure's mission is to become a leading supplier of human cell-based therapies for the treatment of retinal and neural degenerative diseases. Its technology platform is based on the manufacture of diverse cell products sourced from clinical-grade (GMP-compatible) human embryonic stem cells. Its current focus is the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. Cell Cure's major shareholders include BioTime, Inc., HBL Hadasit Bio-Holdings Ltd., Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA), and Asterias Biotherapeutics (OTCBB: ASTY). Additional information about Cell Cure can be found on the web at http://www.cellcureneurosciences.com. A video of a presentation by Cell Cures CEO Dr. Charles Irving is available on BioTimes web site.

About BioTime

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTimes focus is on pluripotent stem cell technology based on human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTimes therapeutic and research products include a wide array of proprietary PureStem progenitors, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (a HyStem product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications, and is planning to initiate a pivotal clinical trial around Renevia, in 2014. In addition, BioTime has developed Hextend, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ HealthCare Corporation, under exclusive licensing agreements.

See the original post here:
BioTimes Subsidiary Cell Cure Neurosciences Ltd. Demonstrates the Safety and Efficacy of OpRegen in Preclinical ...

NUI Galway in joint stem cell project with Mayo Clinic

Joint research projects by NUIG and the Mayo Clinic will focus on a number of key strategic areas, including adult stem-cell therapy, gene therapy, biomaterials and biomedical engineering, the two institutes have said. Illustration: Getty

NUI Galway and the Mayo Clinic in the US plan to collaborate on clinical trials using regenerative medicine, following the signing of a memorandum of understanding between the two institutes.

The joint research projects will focus on a number of key strategic areas, including adult stem-cell therapy, gene therapy, biomaterials and biomedical engineering, the two institutes have said.

The Mayo Clinic and NUIGs Regenerative Medicine Institute have worked closely with each other for a number of years.

Both have licensed cell manufacturing facilities, and student and staff exchange programmes between Galway and the US will continue.

Welcoming the agreement, NUIG president Dr Jim Browne has noted that his university has Irelands only facility licensed to produce stem cells for human use.

A new clinical and translational research facility for conducting clinical trials with patients will be complete in early 2015, he said.

See the rest here:
NUI Galway in joint stem cell project with Mayo Clinic

Better way to track emerging cell therapies using MRIs

Cellular therapeutics -- using intact cells to treat and cure disease -- is a hugely promising new approach in medicine but it is hindered by the inability of doctors and scientists to effectively track the movements, destination and persistence of these cells in patients without resorting to invasive procedures, like tissue sampling.

In a paper published September 17 in the online journal Magnetic Resonance in Medicine, researchers at the University of California, San Diego School of Medicine, University of Pittsburgh and elsewhere describe the first human tests of using a perfluorocarbon (PFC) tracer in combination with non-invasive magnetic resonance imaging (MRI) to track therapeutic immune cells injected into patients with colorectal cancer.

"Initially, we see this technique used for clinical trials that involve tests of new cell therapies," said first author Eric T. Ahrens, PhD, professor in the Department of Radiology at UC San Diego. "Clinical development of cell therapies can be accelerated by providing feedback regarding cell motility, optimal delivery routes, individual therapeutic doses and engraftment success."

Currently, there is no accepted way to image cells in the human body that covers a broad range of cell types and diseases. Earlier techniques have used metal ion-based vascular MRI contrast agents and radioisotopes. The former have proven difficult to differentiate in vivo; the latter raise concerns about radiation toxicity and do not provide the anatomical detail available with MRIs.

"This is the first human PFC cell tracking agent, which is a new way to do MRI cell tracking," said Ahrens. "It's the first example of a clinical MRI agent designed specifically for cell tracking."

Researchers used a PFC tracer agent and an MRI technique that directly detects fluorine atoms in labeled cells. Fluorine atoms naturally occur in extremely low concentrations in the body, making it easier to observe cells labeled with fluorine using MRI. In this case, the modified and labeled dendritic cells -- potent stimulators of the immune system -- were first prepared from white blood cells extracted from the patient. The cells were then injected into patients with stage 4 metastatic colorectal cancer to stimulate an anti-cancer T-cell immune response.

The published study did not assess the efficacy of the cell therapy, but rather the ability of researchers to detect the labeled cells and monitor what happened to them. Ahrens said the technique worked as expected, with the surprising finding that only half of the delivered cell vaccine remained at the inoculation site after 24 hours.

"The imaging agent technology has been to shown to be able to tag any cell type that is of interest," Ahrens said. "It is a platform imaging technology for a wide range of diseases and applications," which might also speed development of relevant therapies.

"Non-invasive cell tracking may help lower regulatory barriers," Ahrens explained. "For example, new stem cell therapies can be slow to obtain regulatory approvals in part because it is difficult, if not impossible, with current approaches to verify survival and location of transplanted cells. And cell therapy trials generally have a high cost per patient. Tools that allow the investigator to gain a 'richer' data set from individual patients mean it may be possible to reduce patient numbers enrolled in a trial, thus reducing total trial cost."

Story Source:

View post:
Better way to track emerging cell therapies using MRIs